^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) + Tyvyt (sintilimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations
Excerpt:
...Patients with genetic testing (allowing PCR and NGS detection methods) confirmed uncommon mutations (EGFR G719X, L861Q, S768I, and 20ins et al.), patients can accept two or more types of EGFR rare co-mutation....
Trial ID:
Source:
Title:
Efficacy of Sintilimab combined with Anlotinib Hydrochloride Capsules in patients with EGFR+ and TKI resistant patients with high PD-L1 expression advanced non-small cell lung cancer
Excerpt:
...NSCLC with positive epidermal growth factor receptor (EGFR) gene mutation; 3. ...
Trial ID:
More C2 evidence
Source:
Title:
Anlotinib Combined with Sintilimab in the First-Line Trentment of Advanced Non-Small Cell Lung Cancer
Excerpt:
...Molecular typing refers to EGFR gene mutation, which was clearly detected by ARMS method. ...
Trial ID:
Source:
Title:
Phase II Clinical Trail of Anlotinib Combined with Sintilimab in the Second-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer.
Excerpt:
...Provide detectable specimens (tissue or pleural effusion specimens) for PD-L1 expression detection and genotype testing*, patients with negative EGFR-sensitive mutations, ALK fusion, and ROS1 fusion gene test would be enrolled; or patients with positive test results but who have received relevant targeted drug treatment and have progressed. ...
Trial ID:
Less C2 evidence
Source:
Title:
Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial
Published date:
09/18/2023
Excerpt:
The combination of sintilimab and anlotinib demonstrated durable efficacy and was generally well tolerated in patients with NSCLC and uncommon EGFR mutations who had received prior standard-of-care treatments.
DOI:
https://doi.org/10.1002/cam4.6548
Trial ID:
